HaemaLogiX Achieves First Patient Dosing Milestone with Targeted KMCAR™ T-Cell Therapy

Multiple myeloma affects approximately 543,000 people globally with 42% mortality within five years of diagnosis; current treatments often cause life-threatening infections due to immune system damage.

In a Sydney clinic in late August, a patient with relapsed multiple myeloma became the first human to receive KMCAR™ T-cell therapy — a genetically engineered treatment designed not merely to fight cancer, but to do so without dismantling the immune defenses that keep a person alive. HaemaLogiX Ltd, after years of laboratory work, has crossed the threshold from theory into the body, and the body, for now, has accepted the offering without alarm. For the roughly 543,000 people living with a disease that remains incurable and claims four in ten lives within five years, this moment represents the

HaemaLogiX Achieves First Patient Dosing Milestone with Targeted KMCAR™ T-Cell Therapy

Cobertura Relacionada

Receba o Register no seu e-mail